{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06423911",
            "orgStudyIdInfo": {
                "id": "HQP1351CG301"
            },
            "organization": {
                "fullName": "Ascentage Pharma Group Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Phase 3 Registrational Study of Olverembatinib (HQP1351) in Patients With CML",
            "officialTitle": "This is a Global, Multi-center, Open-label Randomized and Registrational Phase 3 Study of Olverembatinib (HQP1351) in Patients With Chronic Myeloid Leukemia",
            "acronym": "POLARIS-2",
            "therapeuticArea": [
                "Oncology and Hematology",
                "Other"
            ],
            "study": "a-phase-registrational-study-of-olverembatinib-in-patients-with-cml"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "NOT_YET_RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-05",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-12",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-02",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-05-16",
            "studyFirstSubmitQcDate": "2024-05-16",
            "studyFirstPostDateStruct": {
                "date": "2024-05-21",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-16",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-21",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Ascentage Pharma Group Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "A Global Multicenter, Open Label, Randomized, Phase 3 Registrational Study of Olverembatinib (HQP1351) in Patients with Chronic Phase Chronic Myeloid Leukemia (POLARIS-2)",
            "detailedDescription": "This is a global, multi-center, open-label randomized and registrational phase 3 study of olverembatinib: Part A is a randomized controlled part that is designed to compare the efficacy and safety of olverembatinib (investigational arm) versus bosutinib (control arm) in patients with CML-CP, previously treated with at least two tyrosine kinase inhibitors (TKIs). Part B is to evaluate the efficacy and safety of olverembatinib in the CML- CP patients with T315I mutation."
        },
        "conditionsModule": {
            "conditions": [
                "Chronic Myeloid Leukemia",
                "CML",
                "CML, Chronic Phase"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE3"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "interventionModelDescription": "Part A 2:1 ratio Part B: control",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 285,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Arm A:",
                    "type": "OTHER",
                    "description": "Randomized controlled part that is designed to compare the efficacy and safety of olverembatinib (investigational arm) versus bosutinib (control arm) in patients with CML-CP, previously treated with at least two TKIs",
                    "interventionNames": [
                        "Drug: olverembatinib",
                        "Drug: Bosutinib"
                    ]
                },
                {
                    "label": "Arm B:",
                    "type": "OTHER",
                    "description": "To evaluate the efficacy and safety of olverembatinib in the CML-CP patients with T315I mutation previously",
                    "interventionNames": [
                        "Drug: olverembatinib"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "olverembatinib",
                    "description": "olverembatinib QOD",
                    "armGroupLabels": [
                        "Arm A:",
                        "Arm B:"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Bosutinib",
                    "description": "Bosutnib QD",
                    "armGroupLabels": [
                        "Arm A:"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "MMR rate Part A",
                    "description": "To compare the major molecular response (MMR) rate at 24 weeks of olverembatinib versus bosutinib",
                    "timeFrame": "24 weeks"
                },
                {
                    "measure": "MMR rate Part B",
                    "description": "To evaluate the MMR rate by 24 weeks of olverembatinib in CML-CP patients with T315I mutation",
                    "timeFrame": "24 weeks"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\nPatients eligible for inclusion in this study must meet all of the following criteria.\n\n1. Age \u2265 18 years old.\n2. Diagnosis of CML-CP\n3. Part A: Previously treated with at least two approved TKIs Part B: T315I mutation at screening.\n4. Eastern Cooperative Oncology Group (ECOG) performance status (PS) \u2264 2.\n5. Written informed consent obtained prior to any screening procedures.\n6. Patients with adequate organ functions\n\nExclusion Criteria:\n\nPatients eligible for this study must not meet any of the following criteria.\n\n1. For Part A only: T315I mutation at any time prior to starting study treatment.\n2. Active infection that requires systemic drug therapy\n3. Impairment of gastrointestinal (GI) function or GI disease that may significantly alter absorption of study drugs\n4. Previous treatment with or known / suspected hypersensitivity to olverembatinib or any of its excipients.\n5. Previous treatment with or known / suspected hypersensitivity to bosutinib or any of its excipients.\n6. Pregnant or nursing (lactating) women.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "99 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Ben Little",
                    "role": "CONTACT",
                    "phone": "301-509-3222",
                    "email": "ben.little@ascentage.com"
                },
                {
                    "name": "Huanshan Guo",
                    "role": "CONTACT",
                    "email": "huanshan.guo@ascentage.com"
                }
            ],
            "locations": [
                {
                    "facility": "MD Anderson Cancer Center",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000007938",
                    "term": "Leukemia"
                },
                {
                    "id": "D000007951",
                    "term": "Leukemia, Myeloid"
                },
                {
                    "id": "D000015464",
                    "term": "Leukemia, Myelogenous, Chronic, BCR-ABL Positive"
                },
                {
                    "id": "D000015466",
                    "term": "Leukemia, Myeloid, Chronic-Phase"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000006402",
                    "term": "Hematologic Diseases"
                },
                {
                    "id": "D000009196",
                    "term": "Myeloproliferative Disorders"
                },
                {
                    "id": "D000001855",
                    "term": "Bone Marrow Diseases"
                },
                {
                    "id": "D000002908",
                    "term": "Chronic Disease"
                },
                {
                    "id": "D000020969",
                    "term": "Disease Attributes"
                },
                {
                    "id": "D000010335",
                    "term": "Pathologic Processes"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M10945",
                    "name": "Leukemia",
                    "asFound": "Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M18123",
                    "name": "Leukemia, Myelogenous, Chronic, BCR-ABL Positive",
                    "asFound": "Chronic Myeloid Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10955",
                    "name": "Leukemia, Myeloid",
                    "asFound": "Myeloid Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M18125",
                    "name": "Leukemia, Myeloid, Chronic-Phase",
                    "asFound": "CML, Chronic Phase",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M9490",
                    "name": "Hematologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M12149",
                    "name": "Myeloproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M5134",
                    "name": "Bone Marrow Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M6147",
                    "name": "Chronic Disease",
                    "relevance": "LOW"
                },
                {
                    "id": "M22700",
                    "name": "Disease Attributes",
                    "relevance": "LOW"
                },
                {
                    "id": "T1303",
                    "name": "Chronic Graft Versus Host Disease",
                    "asFound": "Chronic",
                    "relevance": "HIGH"
                },
                {
                    "id": "T1309",
                    "name": "Chronic Myeloid Leukemia",
                    "asFound": "Chronic Myeloid Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "T3995",
                    "name": "Myeloid Leukemia",
                    "asFound": "Myeloid Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "T1311",
                    "name": "Chronic Myeloproliferative Disorders",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000471992",
                    "term": "Bosutinib"
                }
            ],
            "ancestors": [
                {
                    "id": "D000092004",
                    "term": "Tyrosine Kinase Inhibitors"
                },
                {
                    "id": "D000047428",
                    "term": "Protein Kinase Inhibitors"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M42200",
                    "name": "Bosutinib",
                    "asFound": "Perineal",
                    "relevance": "HIGH"
                },
                {
                    "id": "M2889",
                    "name": "Tyrosine Kinase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M25820",
                    "name": "Protein Kinase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "T22",
                    "name": "Tyrosine",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "AA",
                    "name": "Amino Acids"
                }
            ]
        }
    },
    "hasResults": false
}